Tango Therapeutics, Inc.
TNGX
$6.61
$0.111.69%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -24.96% | -18.46% | -28.07% | -23.34% | -9.05% |
Total Depreciation and Amortization | 0.08% | 1.50% | 3.48% | 5.41% | 14.50% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 22.93% | 37.39% | 45.23% | 19.12% | 31.04% |
Change in Net Operating Assets | -15.24% | -5.50% | 16.38% | 38.46% | -43.95% |
Cash from Operations | -23.48% | -11.91% | -11.46% | -2.98% | -11.94% |
Capital Expenditure | -20.74% | 44.60% | 50.59% | 63.43% | 86.49% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 746.52% | 56,723.79% | 102.27% | 2,656.65% | -128.37% |
Cash from Investing | 719.28% | 9,732.98% | 107.90% | 1,449.99% | -131.88% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -96.87% | -96.27% | -42.33% | -40.59% | 9,621.40% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -96.86% | -96.26% | -42.16% | -40.88% | 9,602.85% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 19.87% | -189.39% | -60.87% | 85.26% | 60.76% |